Investment case
Centessa Pharmaceuticals plc
CNTA · 2 developments mapped · last assessed 2026-09-03
Market Ontology has mapped 2 macro, policy, and market developments to Centessa Pharmaceuticals plc since 2026-09-03. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for CNTA yet, so no modelled value is shown. The CNTA valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run CNTA on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Nxera Pharma Secures $8.6M Milestone from Centessa on OX2R Agonist Progress
Advancement of a key pipeline asset (OX2R agonist) increases the probability of future commercial success and potential revenue streams.
· Moves probability of success for ox2r program, peak sales estimates for ox2r agonist, discount rate reflecting reduced development risk
- Main threat
Nxera Pharma Secures $8.6M Milestone from Centessa on OX2R Agonist Progress
Milestone payment outflow for R&D progress, impacting cash flow and potentially increasing R&D expenses.
· Moves r&d expense forecasts, cash burn rate, probability of success for ox2r program
What changed, by assumption
- 2026-09-03Nxera Pharma Secures $8.6M Milestone from Centessa on OX2R Agonist Progress
- 2026-09-03Nxera Pharma Secures $8.6M Milestone from Centessa on OX2R Agonist Progress
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-06-24 | Net debt | Bearish | Liability-management transactions often reduce gross debt or push maturities out. | 0.70 |
| 2026-06-24 | Interest expense | Bearish | Tender/exchange extends maturity profile and typically lowers near-term interest expense. | 0.70 |
| 2026-06-12 | Valuation multiple | Bullish | Target re-rates to bid premium until close. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-03 | Nxera Pharma Secures $8.6M Milestone from Centessa on OX2R Agonist Progress | Bearish | 1-3m | 0.40 |
| 2026-09-03 | Nxera Pharma Secures $8.6M Milestone from Centessa on OX2R Agonist Progress | Bullish | 1-5y | 0.50 |